GRAd-COV2
GRAd-COV2 is a COVID-19 vaccine candidate developed by ReiThera and Lazzaro Spallanzani National Institute for Infectious Diseases.[1][2]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Routes of administration | Intramuscular |
ReferencesEdit
- ^ "GRAd-COV2 Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. 7 January 2021. NCT04528641.
- ^ "ReiThera Announces its GRAd-COV2 COVID-19 Vaccine Candidate is Well Tolerated and Induces Clear Immune Responses in Healthy Subjects Aged 18–55 Years". ReiThera Srl. Yahoo! Finance. 24 November 2020. Retrieved 12 January 2021.
External linksEdit
Scholia has a profile for GRAd-COV2 (Q98945351). |